Drugs / Insulin Lispro Mix25
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01773473 | Jan 2013 → Aug 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03606018 | Apr → Jul 2017 | — | Geropharm | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00551356 Comparator | Nov 2002 → Jul 2003 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Lispro Mix25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01773473 ↗ |
| Known as | LM25 | “compare the efficacy and safety of insulin lispro mix 25 (LM25) and insulin lispro mix 50 (LM50) as starter insulins.” PMID 29574635 ↗ Mar 2018 |
| Route | Subcutaneous | “Insulin lispro mix 25 given SC twice-daily” NCT00551356 ↗ |